CMV prevention strategies in allogeneic hematopoietic cell transplantation; the role of prophylaxis and pre‐emptive monitoring in the era of letermovir

Abstract

AbstractThe preferred strategy for preventing CMV in at‐risk populations in alloHCT has undergone a significant practice shift in recent years where the pendulum has swung from a pre‐emptive approach to now offering letermovir prophylaxis to all CMV seropositive recipients. Letermovir prophylaxis has resulted in significant reductions in post‐transplant clinically significant CMV infection (csCMVi) as well as other important outcomes such as CMV disease, resistant, and refractory CMV infections and nonrelapse mortality. However, prophylactic strategies are not without some limitations, namely delayed onset CMV infections, delayed CMV‐specific T cell immune reconstitution, increased drug costs and limited data within pediatric populations. Thus, this review aims to provide an overview of prophylaxis and pre‐emptive CMV preventative strategies, and how they are applicable in the current era of letermovir prophylaxis.